Real-World Treatment Duration in ALK-Positive Non-Small-Cell Lung Cancer Patients Receiving Brigatinib Through the Early Access Program

References

• Bray F , FerlayJ, SoerjomataramIet al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Zappa C , MousaSA. Non-small cell lung cancer: current treatment and future advances. Transl. Lung Cancer Res.5(3), 288–300 (2016).
   PubMed Web of Science ®Google Scholar
• Gainor JF , VargheseAM, OuSHet al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin. Cancer Res.19, 4273–4281 (2013).
   PubMed Web of Science ®Google Scholar
• Wong DW , LeungEL, SoKKet al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer115, 1723–1733 (2009).
   PubMed Web of Science ®Google Scholar
• Koivunen JP , MermelC, ZejnullahuKet al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res.14, 4275–4283 (2008).
   PubMed Web of Science ®Google Scholar
• Rodig SJ , Mino-KenudsonM, DacicSet al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res.15(16), 5216–5223 (2009).
   PubMed Web of Science ®Google Scholar
• Solomon BJ , KimD, WuYet al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non–small-cell lung cancer. J. Clin. Oncol.36(22), 2251–2258 (2018).
   PubMed Web of Science ®Google Scholar
• Planchard D , PopatS, KerrKet al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.29(Suppl. 4), iv192–iv237 (2018).
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology . Non-small cell lung cancer (2019). www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Katayama R , ShawAT, Mino-KenudsonMet al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med.4(120), 120ra17 (2012).
   PubMed Web of Science ®Google Scholar
• Costa DB , ShawAT, OuSIet al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases. J. Clin. Oncol.33(17), 1881–1888 (2015).
   PubMed Web of Science ®Google Scholar
• Camidge DR , DziadziuszkoR, PetersSet al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small-cell lung cancer in the global Phase III ALEX study. J. Thorac. Oncol.14(7), 1233–1243 (2019).
   PubMed Web of Science ®Google Scholar
• Soria JC , TanDSW, ChiariRet al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, Phase III study. Lancet389(10072), 917–929 (2017).
   PubMed Web of Science ®Google Scholar
• Shaw AT , KimTM, CrinoLet al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol.18(7), 874–886 (2017).
   PubMed Web of Science ®Google Scholar
• Kim DW , TiseoM, AhnMJet al. Brigatinib in patients with crizotinib refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J. Clin. Oncol.35(22), 2490–2498 (2017).
   PubMed Web of Science ®Google Scholar
• Camidge DR , KimHR, AhnMJet al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N. Engl. J. Med.379(21), 2027–2039 (2018).
   PubMed Web of Science ®Google Scholar
• Camidge DR , KimDW, TiseoMet al. Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials. J. Clin. Oncol.36(26), 2693–2701 (2018).
   PubMed Web of Science ®Google Scholar
• Solomon BJ , BesseB, BauerTMet al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol.19(12), 1654–1667 (2018).
   PubMed Web of Science ®Google Scholar
• Gainor JF , DardaeiL, YodaSet al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov.6(10), 1118–1133 (2016).
   PubMed Web of Science ®Google Scholar
• Lin JJ , RielyGJ, ShawAT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov.7(2), 137–155 (2017).
   PubMed Web of Science ®Google Scholar
• US FDA. Pfizer Inc . Lorbrena (lorlatinib) [package insert] (2020). www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf
   Google Scholar
• Reck M , MokTSK, NishioMet al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med.7(5), 387–401 (2019).
   PubMed Web of Science ®Google Scholar
• Descourt R , PerolM, Rousseau-BussacGet al. Brigatinib in pretreated patients with ALK-positive advanced NSCLC. Lung Cancer.136, 109–114 (2019).
   PubMed Web of Science ®Google Scholar
• Hochmair M , WeinlingerC, SchwabSet al. Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. Anticancer Drugs30(7), e0787 (2019).
   PubMed Web of Science ®Google Scholar
• Lin HM , PanX, HouPet al. Treatment duration of brigatinib in patients enrolled in the international Expanded Access Program (EAP). Ann. Oncology.30(Suppl. 2), ii38–ii68 (2019).
   Google Scholar
• Blumenthall GM , GongY, KehlKet al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small cell lung cancer. Ann. Oncol.30(5), 830–838 (2019).
   PubMed Web of Science ®Google Scholar
• Lin HM , PanX, HouPet al. PCN308 Real-world utilization of brigatinib in patients with non-small cell lung cancer (NSCLC). Value Health22(Suppl. 2), S115 (2019).
   Google Scholar
• DiBonaventura MD , WongW, Shah-ManekBet al. Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA. Onco. Targets. Ther.11, 75–82 (2017).
   PubMed Web of Science ®Google Scholar
• Bendaly E , DalalAA, CulverKet al. Treatment patterns and early outcomes of ALK-positive non-small cell lung cancer patients receiving ceritinib: a chart review study. Adv. Ther.34, 1145–1156 (2017).
   PubMed Web of Science ®Google Scholar
• Stinchcombe T , DoebeleRC, WangXFet al. Preliminary results of single arm Phase II trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC). J. Clin. Oncol.37(Suppl. 15), 9027 (2019).
   Web of Science ®Google Scholar
• Novello S , BrustugunOT, CadranelJet al. Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the use via expanded access to brigatinib (UVEA-Brig) study. Ann. Oncol.30(Suppl. 5), mdz260.067 (2019).
   Google Scholar